ATP2B4 and cutaneous melanoma: However, we found a significantly increased progression-free survival of the female patients with primary cutaneous melanoma with high (n = 41) PMCA4 mRNA levels when compared to low (n = 116) transcript levels (55 versus 29 months, p = 0.0037).